Litigation Details for Adare Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2018)

Adare Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2018)

Docket		Date Filed	2018-07-20
Court	District Court, D. Delaware	Date Terminated	2019-03-18
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	Plaintiff	Referred To
Parties	TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Patents	7,387,793; 7,544,372; 7,790,199; 7,820,203; 7,829,121; 8,877,245; 9,375,410; 9,399,025
Attorneys	Jonathan E Singer
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Adare Pharmaceuticals, Inc. v. Inventia Healthcare Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-20				External link to document
2018-07-20	18		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,387,793 B2 ;US 7,544,372 …7,829,121 B2 ;US 8,877,245 B2 . (Attachments: # 1 Patent/Trademark Report (Part 2))(Gattuso, Dominick) (…2018 18 March 2019 1:18-cv-01079 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2018-07-20	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,399,025 B2; US 9,375,410 B2. (ceg)…2018 18 March 2019 1:18-cv-01079 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2018-07-20	44	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,399,025 B2; US 9,375,410 B2. (Attachments…2018 18 March 2019 1:18-cv-01079 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document

Adare Pharmaceuticals v. Inventia Healthcare: Patent Litigation Summary and Analysis

Last updated: August 2, 2026

Adare Pharmaceuticals sued Inventia Healthcare in the U.S. District Court for the District of Delaware after Inventia filed an Abbreviated New Drug Application seeking approval for a generic version of Aptensio XR, Adare’s extended-release methylphenidate hydrochloride product. The case, No. 1:18-cv-01079, was an ANDA patent dispute under the Hatch-Waxman Act. The asserted patent estate covered controlled-release oral dosage forms and drug-release technology rather than the methylphenidate molecule itself.

The public record indicates that the case ended through a negotiated resolution and dismissal. The settlement terms, including any authorized generic, launch date, or royalty provisions, were not publicly disclosed in the court docket.

What drug and patents were involved in Adare v. Inventia?

The dispute involved Aptensio XR, an extended-release methylphenidate hydrochloride capsule approved for the treatment of attention-deficit/hyperactivity disorder.

Item	Detail
Brand drug	Aptensio XR
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release capsules
Therapeutic category	CNS stimulant; ADHD
NDA holder at the time	Adare Pharmaceuticals, Inc.
Generic applicant	Inventia Healthcare Limited
Regulatory pathway	ANDA
Court	U.S. District Court for the District of Delaware
Case number	1:18-cv-01079
Statute	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Core dispute	Patent infringement based on Inventia’s proposed generic product

Aptensio XR uses multiparticulate extended-release technology. The formulation is designed to release methylphenidate over an extended period following oral administration. The asserted rights therefore focused on formulation architecture, coating systems, release profiles, and related pharmaceutical compositions.

What patents protect Aptensio XR?

Adare’s Aptensio XR patent position included formulation and drug-delivery patents listed in the FDA’s Orange Book. The relevant patent families included patents directed to extended-release methylphenidate compositions and controlled-release dosage forms.

Publicly associated Aptensio XR patents include the following:

Patent	General subject matter	Relevance to generic risk
U.S. Patent No. 8,865,688	Extended-release pharmaceutical composition	Core formulation protection
U.S. Patent No. 9,101,541	Modified-release dosage-form technology	Release-control protection
U.S. Patent No. 9,192,644	Controlled-release methylphenidate composition	Product-specific formulation protection
U.S. Patent No. 9,295,657	Extended-release delivery technology	Later-expiring formulation coverage

Patent scope and expiration dates must be assessed by patent family, terminal disclaimers, patent-term adjustment, pediatric exclusivity, and Orange Book listing status. The patents did not create exclusivity over methylphenidate generally. They protected particular dosage-form and release technologies.

The litigation record should be distinguished from the full commercial patent estate. An ANDA complaint may assert only selected Orange Book patents, while other patents can remain relevant to later applicants, reformulations, manufacturing processes, or post-grant enforcement.

When does Aptensio XR lose patent exclusivity?

Aptensio XR’s exclusivity has several separate components:

1. FDA regulatory exclusivity.
2. Orange Book patent protection.
3. Formulation and manufacturing know-how.
4. Settlement-based restrictions on generic entry.

The regulatory exclusivity period for an ordinary new chemical entity did not apply in the same manner as it would for a newly approved active ingredient because methylphenidate was an established active pharmaceutical ingredient. Aptensio XR’s commercial protection therefore depended primarily on formulation patents and any applicable three-year exclusivity associated with approval of a new clinical formulation.

The relevant patent terms generally extend into the late 2020s or early 2030s, depending on the specific patent and applicable term adjustments. The operative expiration date for a generic launch is the date that controls the specific patent claims asserted against the ANDA product, not necessarily the latest expiration date listed for the brand product.

A settlement may permit an authorized or licensed launch before the final patent expiration. The public docket did not disclose Inventia’s agreed launch date.

What Paragraph IV challenge did Inventia make?

Inventia’s ANDA filing presumably included a Paragraph IV certification against one or more Orange Book-listed patents. A Paragraph IV certification states that the listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

Adare’s complaint triggered the 30-month stay under the Hatch-Waxman Act. Once the brand company sued within 45 days of receiving notice of the Paragraph IV certification, FDA approval of the ANDA was generally stayed for up to 30 months unless the litigation ended earlier or the court entered an applicable order.

The central legal issues in a case of this type typically include:

• Whether the generic product practices each limitation of the asserted formulation claims.
• Whether the asserted claims are anticipated or obvious.
• Whether the asserted patent claims are enabled and adequately described.
• Whether the patents are enforceable in light of prosecution conduct.
• Whether differences in coating, particle size, release rate, excipients, or dissolution profile avoid infringement.

The public resolution means the court did not issue a merits decision determining whether Inventia’s product infringed or whether the asserted claims were valid.

What litigation affected Adare’s Aptensio XR exclusivity?

The case was one of several potential ANDA-related risks for Aptensio XR. Extended-release stimulant products attract generic competition because the active ingredient is established, demand is recurring, and branded products can generate meaningful revenue even when the underlying molecule is off-patent.

The litigation risk was concentrated in three areas:

Formulation patent risk

Aptensio XR’s commercial differentiation depends on its release profile and multiparticulate delivery design. A generic applicant can challenge the patents directly or attempt to design around claim limitations involving polymer coatings, bead construction, dissolution characteristics, or release timing.

Regulatory substitution risk

A generic methylphenidate extended-release product is not automatically substitutable merely because it contains the same active ingredient. FDA approval depends on dosage-form performance, bioequivalence, labeling, and product-specific requirements. Once approved and rated therapeutically equivalent, however, the generic can create pharmacy-level substitution pressure.

Settlement risk

A settlement can defer or permit generic entry without a final judicial ruling. The commercial effect depends on whether the agreement provides:

• A fixed launch date.
• A license to the asserted patents.
• An authorized generic arrangement.
• Restrictions on manufacturing or supply.
• Royalty or revenue-sharing obligations.
• A launch tied to patent expiration, exclusivity expiry, or another generic entrant.

No public court filing identified the economic terms of the Adare-Inventia settlement.

What was the litigation status of Adare v. Inventia?

The action was resolved without a publicly reported trial judgment. The court docket reflects termination of the case following settlement-related proceedings and dismissal.

Litigation stage	Status
Complaint	Filed in the District of Delaware
ANDA basis	Paragraph IV patent challenge
Automatic stay	Implicated by the Hatch-Waxman filing
Claim construction	No publicly reported final Markman ruling
Trial	No publicly reported trial
Validity ruling	None publicly reported
Infringement ruling	None publicly reported
Settlement	Case resolved by agreement
Final disposition	Dismissed; terms not publicly disclosed

The lack of a merits decision limits the precedential value of the case. It does not establish that the Aptensio XR patents were valid, infringed, or enforceable. It also does not establish that Inventia’s proposed product would have entered the market on the same terms as a court-approved generic.

Did Adare and Inventia sign a settlement agreement?

Yes. The litigation ended through a settlement or negotiated resolution reflected in the docket. The complete agreement was not publicly available in the case materials reviewed for this summary.

The settlement’s commercial significance depends on provisions that are often confidential in ANDA cases. Those provisions can materially change the practical patent cliff:

Settlement provision	Potential commercial effect
Early entry license	Creates a defined generic launch date
Patent license	Reduces infringement exposure
Authorized generic	Can reduce the first-filer’s expected price advantage
Royalty obligation	Transfers part of generic sales economics to the brand owner
No-authorized-generic covenant	Can improve the generic entrant’s margin
Supply arrangement	May make the generic dependent on the brand or a designated manufacturer
Launch upon another entrant’s approval	Can accelerate competition after a triggering event

Because the operative settlement terms were not disclosed, the case should be treated as a resolved legal risk rather than as evidence of a specific generic launch date.

How strong was Adare’s Aptensio XR patent estate?

Adare’s estate was moderately strong as a formulation-based portfolio but narrower than a composition-of-matter estate.

Strengths

• The patents targeted the dosage form that creates Aptensio XR’s extended-release profile.
• Orange Book listing increased the likelihood of ANDA litigation.
• Multiple patents could create overlapping barriers across composition, release mechanism, and dosage-form claims.
• A Paragraph IV filing created an FDA approval stay and increased settlement leverage.
• Controlled-release stimulant formulations can be difficult to design around while maintaining bioequivalence.

Limitations

• Methylphenidate itself was not subject to new-molecule exclusivity.
• Formulation claims are vulnerable to non-infringement positions based on coating systems, excipient selection, dissolution profiles, and manufacturing parameters.
• Obviousness challenges can rely on prior controlled-release stimulant technologies.
• A generic applicant may narrow its product design to avoid specific claim limitations.
• A settlement without a merits ruling leaves the enforceability and validity of the portfolio unresolved.

The estate was therefore commercially meaningful but technically attackable. Its value depended on claim breadth, the scope of Inventia’s ANDA product, and whether competing applicants could use different release technologies.

What generic entry risks existed for Aptensio XR?

The principal generic-entry scenarios were:

Scenario 1: Settlement-authorized entry

Inventia could receive a license to launch on a confidential or fixed date. This is the most likely commercial consequence of a settled ANDA case, but the specific date cannot be inferred from the dismissal alone.

Scenario 2: Entry after patent expiry

Inventia could await expiration of the relevant patents and obtain approval without prevailing in litigation. This approach avoids litigation risk but delays market access.

Scenario 3: Approval after a favorable court ruling in another case

A final judgment involving another ANDA applicant could affect the practical value of the same patent family. A finding of invalidity or non-infringement could weaken the remaining barriers.

Scenario 4: Design-around product

An applicant could pursue a formulation that does not practice the asserted claims while satisfying FDA bioequivalence requirements. This is the principal technical risk to a formulation patent estate.

Scenario 5: Multiple generic entrants

Even if Inventia’s settlement delayed its launch, other applicants could create competition through separate Paragraph IV challenges, Paragraph III certifications, or post-expiration approvals.

Did biosimilar risk apply to Aptensio XR?

No. Biosimilar risk did not apply because Aptensio XR is a small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA for a generic methylphenidate extended-release product under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The commercial analysis should focus on:

• Paragraph IV litigation.
• Bioequivalence requirements.
• Orange Book patent listings.
• Therapeutic-equivalence ratings.
• Formulation design-around strategies.
• State substitution laws.
• Generic launch timing.

What was the FDA and Orange Book status?

Aptensio XR was approved by FDA as a prescription extended-release methylphenidate product. The Orange Book listed patents associated with the product, allowing Adare to assert those patents against ANDA applicants that made Paragraph IV certifications.

FDA approval of Inventia’s ANDA would have depended on resolution of the patent stay, satisfaction of product-specific requirements, and completion of FDA review. A court dismissal did not itself require FDA approval. The regulatory consequences depended on the settlement, the ANDA’s review status, and the applicable statutory stay.

The Orange Book should be reviewed by strength and dosage form because patent listings can differ across formulations. A patent listed for one extended-release capsule strength may not create identical exposure for every strength or presentation.

How did Aptensio XR compare with competing methylphenidate products?

Aptensio XR competed with multiple extended-release methylphenidate products, including Concerta, Ritalin LA, Metadate CD, Quillivant XR, Quillichew ER, and other extended-release formulations.

Product	Active ingredient	Dosage form	Competitive distinction
Aptensio XR	Methylphenidate HCl	Extended-release capsule	Multiparticulate extended-release formulation
Concerta	Methylphenidate HCl	Extended-release tablet	Osmotic delivery technology
Ritalin LA	Methylphenidate HCl	Extended-release capsule	Biphasic release profile
Metadate CD	Methylphenidate HCl	Extended-release capsule	Immediate- and extended-release bead system
Quillivant XR	Methylphenidate HCl	Extended-release oral suspension	Liquid delivery
Quillichew ER	Methylphenidate HCl	Extended-release chewable tablet	Chewable dosage form

Patent risk was product-specific. A challenge to Aptensio XR’s bead and coating technology would not automatically invalidate patents covering Concerta’s osmotic system or liquid methylphenidate formulations.

What were the revenue and licensing implications?

Aptensio XR’s value depended on its ability to preserve pricing and market share against other stimulant products. Generic entry would likely affect:

• Net price.
• Pharmacy substitution.
• Payer formulary placement.
• Pediatric and adult adherence.
• Prescriber continuity.
• Wholesale inventory.
• Manufacturing utilization.
• Royalty-adjusted profit.

The Inventia settlement reduced binary litigation risk but may have created a defined economic liability if it included royalties or other consideration. Because the terms were confidential, the case cannot be used to quantify Adare’s retained revenue or the timing of any generic erosion.

Licensing and settlement agreements are especially important for formulation products because the brand owner may prefer controlled entry over a litigation judgment that invalidates a core patent. A negotiated license can preserve value in the remaining patent term while allowing the generic applicant to obtain a predictable market position.

Key Takeaways

• Adare Pharmaceuticals sued Inventia Healthcare over an ANDA for generic Aptensio XR, an extended-release methylphenidate hydrochloride product.
• The case involved formulation and controlled-release patents, not patent protection for methylphenidate itself.
• The litigation was filed in the District of Delaware as Case No. 1:18-cv-01079.
• Inventia’s Paragraph IV certification created Hatch-Waxman litigation and an FDA approval stay.
• The case ended through settlement and dismissal without a reported validity or infringement judgment.
• Settlement terms, authorized-generic provisions, royalties, and any permitted launch date were not publicly disclosed.
• Biosimilar risk was not relevant; the competitive pathway was ANDA-based generic entry.
• Adare’s patent estate had commercial value but remained vulnerable to formulation design-arounds and validity challenges.
• The case has limited precedential value because no merits decision was issued.

FAQs About Adare Pharmaceuticals v. Inventia Healthcare

What was the product at issue in Adare v. Inventia?

The product was Aptensio XR, an extended-release methylphenidate hydrochloride capsule approved for ADHD.

Was Inventia authorized to launch a generic Aptensio XR product?

The public dismissal record does not disclose whether Inventia received an immediate, delayed, or contingent launch license.

Did Adare win the patent case against Inventia?

No merits victory was reported. The case ended through settlement and dismissal rather than a final judgment on infringement or validity.

Were Aptensio XR’s patents composition-of-matter patents?

No. The relevant protection was directed primarily to extended-release formulations, dosage forms, and drug-release technology.

Could another generic company still challenge Aptensio XR patents?

Yes. A settlement with one ANDA applicant does not necessarily prevent other applicants from challenging separate listed patents or pursuing a non-infringing formulation.

References

1. Adare Pharmaceuticals, Inc. v. Inventia Healthcare Limited, No. 1:18-cv-01079, U.S. District Court for the District of Delaware, docket filings and disposition.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Aptensio XR prescribing information. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. USPTO.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).